HELP (Helus Pharma) Change In Receivables: $-0.93 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HELP Helus Pharma Inc HELP
34 GF Score
Price $12.61
! 3 Warning Signs
View Full Analysis

What is Helus Pharma Change In Receivables?

Helus Pharma HELP +0.80% 34 Change In Receivables is $-0.93 Mil as of Jun. 2026. GuruFocus rates HELP with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.

Helus Pharma's change in receivables for the quarter that ended in Jun. 2026 was $-0.01 Mil. It means Helus Pharma's Accounts Receivable increased by $0.01 Mil from Mar. 2026 to Jun. 2026 .

Helus Pharma's change in receivables for the fiscal year that ended in Mar. 2026 was $-0.93 Mil. It means Helus Pharma's Accounts Receivable increased by $0.93 Mil from Mar. 2025 to Mar. 2026 .

Helus Pharma's Accounts Receivable for the quarter that ended in Jun. 2026 was $5.04 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Helus Pharma's liquidation value for the three months ended in Jun. 2026 was $152.58 Mil.

Helus Pharma  (NAS:HELP) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Helus Pharma's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=5.038/0*91
=

2. In Ben Graham's calculation of liquidation value, Helus Pharma's accounts receivable are only considered to be worth 75% of book value:

Helus Pharma's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=166.365-17.568+0.75 * 5.038+0.5 * 0
=152.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helus Pharma Change In Receivables Related Terms

Helus Pharma Change In Receivables Historical Data

* Premium members only.

The historical data trend for Helus Pharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helus Pharma Change In Receivables Chart

Helus Pharma Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Change In Receivables
Get a 7-Day Free Trial -0.62 -0.70 -0.81 -0.79 -0.93

Helus Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.63 -0.03 -0.26 -0.01
HELP
34GF Score
Helus Pharma Inc HELP
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Helus Pharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $-0.93 Mil mean?
Helus Pharma (HELP) has a Change In Receivables of $-0.93 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Helus Pharma and its competitors.
Is Helus Pharma's Change In Receivables too high?
Helus Pharma's current Change In Receivables is $-0.93 Mil. Overall, Helus Pharma has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Helus Pharma's Change In Receivables compare to VRTX and REGN?
Helus Pharma's Change In Receivables of $-0.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Helus Pharma and its competitors. Helus Pharma's current Change In Receivables is $-0.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helus Pharma stock overvalued right now?
Helus Pharma (HELP) has a current Change In Receivables of $-0.93 Mil. The current Change In Receivables is $-0.93 Mil. Helus Pharma's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Helus Pharma (HELP), the current Change In Receivables is $-0.93 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helus Pharma Business Description

Other Exchanges R7E:GermanyHELP:Canada
Address 100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
34GF Score

Get the complete analysis for HELP

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.61
Price